Form 4: Cogent Biosciences Director Acquires Stock Options

Director Todd Shegog acquired stock options in Cogent Biosciences, Inc. on June 5, 2024.

Summary

• Todd Shegog, a director of Cogent Biosciences, Inc., filed a Form 4 on June 13, 2024.
• The filing reports a transaction that occurred on June 5, 2024, where Shegog acquired stock options.
• Shegog acquired options to purchase 44,700 shares of common stock at an exercise price of $8.92.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders and expire on June 5, 2034.
• Following the transaction, Shegog directly owns 44,700 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Cogent Biosciences.
• Comparing the vesting schedule and exercise price to similar grants at companies like Blueprint Medicines or Relay Therapeutics would provide context on the competitiveness of this compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates